Navigation Links
Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials

/p>

"EVEREST adds to the collection of data on tolvaptan and its potential uses," said Kazumichi Kobayashi, Chairman & CEO of Otsuka Pharmaceutical Development & Commercialization, Inc. "Tolvaptan, as one of our most advanced candidate therapies, exemplifies the successful application of Otsuka's expertise in new drug research and development."

About Heart Failure

More than 14 million people in Europe(6) and five million U.S. residents(7) have heart failure (HF), a serious chronic condition in which the heart cannot effectively pump blood. The direct and indirect U.S. health care expenses related to HF tally about $28 billion, ACC estimates.(5) The majority of patients hospitalized for ADHF, the worsening of chronic HF that affects 1 million US residents annually, have edema or excess body fluid.(3)

About Otsuka Pharmaceutical Development & Commercialization, Inc.

Otsuka Pharmaceutical Development and Commercialization, Inc. is involved in conducting all phases of clinical research and development of innovative healthcare products to address unmet medical needs. OPDC is well established in the scientific community as a globally focused organization that plays a leadership role in the research and development of Otsuka's ethical healthcare products. The Company is dedicated to the improvement of the quality of human life and health of patients around the world with a strong commitment to research and development in the areas of cardiovascular, neuroscience, renal and respiratory diseases, as well as cancer and ophthalmic disorders. OPDC is part of the Otsuka Pharmaceutical Group, which is comprised of 87 companies and approximately 27,000 people around the world. With 44 consolidated subsidiaries, Otsuka earned US $6.8 billion in consolidated annual revenues in fiscal 2005. For additional information, visit www.otsuka.com.

JAMA Publications:

Konstam, MA, et
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
2. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
3. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
4. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
5. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
6. Surfaxin (Lucinactant) Long-Term Survival Advantage vs. Comparators Published in Pediatrics
7. Long-Term Extension of Ulcerative Colitis Study Shows Remicade Responders Maintained Improvement Through Two Years of Follow-Up
8. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia
9. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
10. Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes for Moderate-Release Paclitaxel-Eluting Stent at Four Years
11. UCB Presents Long-Term CImzia Data in Crohns Disease
Post Your Comments:
(Date:7/24/2014)... -- Abaxis, Inc. (NasdaqGS: ABAX ), a medical ... financial results for the first fiscal quarter ended June ... Revenues of $47.5 million, up 10% over last year,s ... 50% over last year,s comparable quarter. Revenues ... up 20% over last year,s comparable quarter. , ...
(Date:7/24/2014)... 24, 2014  IRIDEX Corporation (NASDAQ: IRIX ... quarter 2014 financial results after the market closes on ... the release, the Company will host a conference call ... Time on Thursday, July 31, 2014 ... business developments. Interested parties may access the ...
(Date:7/24/2014)... , July 24, 2014 Omnicell, Inc. ... of medication and supply management solutions and analytics ... Thursday, July 31, to discuss the Company,s Second ... Second Quarter 2014 earnings conference call and webcastWhen: ... , Randall Lipps, chairman, president and chief executive ...
Breaking Medicine Technology:Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2
... , June 28 Preliminary results of ... and hypertension demonstrated that the investigational triple combination therapy ... resulted in a statistically significant greater Least Squares (LS) ... 12 (37.9/22.0 mm Hg versus 26.4-28.0/14.7-17.6 mm Hg, P ...
... Tolerx, Inc., a biopharmaceutical company developing novel ... T cell activity, today announced the initiation of a ... in autoimmune new-onset type 1 diabetes. The confirmatory Phase ... For Early or New-Onset Type 1 Diabetes) and immediately ...
Cached Medicine Technology:New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 2New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 3New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 4New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 5New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 6New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 7Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes 2Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes 3Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes 4
(Date:7/25/2014)... As reported by the Statesman Journal in the ... (7/20), police in Salem, MA as well as several other ... heroin epidemic that has taken many lives during the past ... case in which police were able to make two arrests ... pretending to be the victim and claiming to want to ...
(Date:7/25/2014)... (HealthDay News) -- Seniors are more easily distracted during ... study finds. "Almost any type of memory test ... of 25 on," study co-author Randi Martin, professor of ... release. However, Martin said, this study shows that ... older adults compared with younger adults. The study ...
(Date:7/25/2014)... 25, 2014 Reproductive Science Center (RSC) ... Dr. Kerri Luzzo, Lead Physician at RSC Rhode Island, ... professional accomplishments in fertility care and community outreach issued ... 10th Annual PBN Awards ceremony held July 24th at ... the most highly regarded, emerging leaders in their field ...
(Date:7/25/2014)... July 25, 2014 (HealthDay News) -- The human brain ... of dehydration, a new study finds. Although ... in England have found that the brain compensates by ... blood. "This research has helped us understand a ... extreme exercise in extreme conditions," study first author Steven ...
(Date:7/25/2014)... York, ON (PRWEB) July 25, 2014 A ... Michael’s Hospital revealed that 39 percent of all children in ... a dentist. , The survey looked at 2,505 children during the ... all around four years of age. The final result was ... any dental care. Many of these children were from lower-income families ...
Breaking Medicine News(10 mins):Health News:Multiple States Crack Down on Heroin Epidemic 2Health News:Distractions Seem More Troublesome With Age 2Health News:Dr. Kerri Luzzo of the Reproductive Science Center of Providence Receives “40 Under Forty Award" for Outstanding Professional Accomplishments and Community Outreach 2Health News:Human Brain Has Coping Mechanism for Dehydration 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 3
... By Jenifer Goodwin HealthDay Reporter , ... of parents with health insurance say they haven,t gotten ... new survey in Ohio finds. Parents of kids ... those with public health insurance such as Medicaid or ...
... Medical Center,s Reinberger Neuroscience Intensive Care Unit (NSU) has ... This is a top honor from the American Association ... The NSU joins four other intensive care units ... been recognized with Beacon Awards: Medical Intensive Care ...
... The roots of cassava ( Manihot esculenta ) serve ... of people in many arid regions of the world, ... Unfortunately the roots of commercial cassava cultivars are ... in these regions. In addition to programs designed ...
... HealthDay Reporter , MONDAY, Oct. 4 (HealthDay News) -- ,A ... prompt healthy lifestyle changes in families, new research sUggests. ... program where they were given a list of health-promoting activities ... the family diet, exercising more as a family and reducing ...
... Diagnostic X-rays may increase the risk of developing ... at the University of California, Berkeley,s School of Public ... with acute lymphoid leukemia (ALL) had almost twice the ... X-rays compared with children who did not have leukemia. ...
... When girls with symptoms of autism or ADHD seek professional ... and there is a real risk that they will not ... training is needed in this area,particularly in the public sector, ... thesis focuses primarily on 100 girls who, before reaching adulthood, ...
Cached Medicine News:Health News:Many Kids Not Getting Recommended Care: Survey 2Health News:Many Kids Not Getting Recommended Care: Survey 3Health News:University Hospitals Case Medical Center's neuroscience intensive care unit earns Beacon Award 2Health News:Using cassava to address vitamin A deficiency 2Health News:Companies Can Motivate Families to Live Healthier 2Health News:Companies Can Motivate Families to Live Healthier 3Health News:X-rays linked to increased childhood leukemia risk 2Health News:X-rays linked to increased childhood leukemia risk 3Health News:X-rays linked to increased childhood leukemia risk 4Health News:Girls with autism or ADHD symptoms not taken seriously 2
... The Epi-K is a fully automated ... surgeons to,perform a new refractive procedure ... to,mechanically cleave the epithelium from the,Bowmans ... laser ablation.,Epi-Lasik preserves the structural integrity,of ...
... The Titan Procedure is a ... infrared light source to tighten skin ... The Titan heats the dermis to ... epidermis through continuous cooling. In addition, ...
... Confidence…real time , ... system for permanent, ... XLTEK ... IOM system. Both configurations feature ...
... Combining exceptional new ... design, XLTEKs latest innovation, ... delivers biphasic intracranial stimulation ... and 300 volts and ...
Medicine Products: